Skip to content

US · ZYME · BIOTECHNOLOGY

Zymeworks Inc. (ZYME) intrinsic value and stock valuation

$26.14as of 2026-11-21 · Mkt cap 1.73B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Zymeworks Inc. DCF and intrinsic value

InvestorsCraft values ZYME with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ZYME’s statements →

Zymeworks Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Middletown, DE 19709 zymeworks.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$106M+22.2% 5y CAGRd
20142025
Net income
-$-81.13M
20142025
Free cash flow
-$-34.53M
20142025
Total equity
$268.5M-8.1% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$106M$76.3M$76M$412.5M$26.7M
Operating income-$-92.53M-$-137.11M-$-138.05M$130.5M-$-215.63M
Net income-$-81.13M-$-122.69M-$-118.67M$124.3M-$-211.84M
EPSd-$-1.08M-$-1.62M-$-1.72M$1.91M-$-4.06M
Operating cash flow-$-33.01M-$-110.04M-$-118.3M$144.1M-$-192.45M
Capital expenditure-$-1.52M-$-3.07M-$-4.08M-$-13.12M-$-13.29M
Free cash flow-$-34.53M-$-113.11M-$-122.38M$131M-$-205.74M
Total assets$346.5M$463.1M$580.9M$648.7M$389.1M
Total debt$18.3M$18.5M$26.7M$28.1M$32.3M
Net debt-$-22.89M-$-47.6M-$-130.84M-$-372.8M-$-169.53M
Total equity$268.5M$338.8M$464.8M$493M$249.1M
Cash and short-term investments$228.8M$225.8M$374.3M$492.2M$252.6M
Income statement
20252024202320222021
Revenue$106M$76.3M$76M$412.5M$26.7M
Cost of revenue$0.00$0.00$143M$0.00$0.00
Gross profit$106M$76.3M-$-66.98M$412.5M$26.7M
Research and development expenses$137M$134.6M$143.6M$208.6M$199.8M
Selling, general and administrative expenses$61.5M$61.5M$70.4M$73.4M$42.6M
Other expenses$0.00$17.3M-$-142.94M-$-40K-$-40K
Operating expenses$198.5M$213.4M$71.1M$282M$242.3M
Cost and expenses$198.5M$213.4M$214.1M$282M$242.3M
Interest income$13.4M$19.9M$19.7M$3.6M$1.97M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$11.1M$11.2M$17.3M$12M$9.58M
Ebitda-$-68.64M-$-108.62M-$-120.7M$142.5M-$-206.09M
Operating income-$-92.53M-$-137.11M-$-138.05M$130.5M-$-215.63M
Total other income/expenses, net$12.8M$20.5M$18.8M$4.71M$3.27M
Income before tax-$-79.75M-$-116.61M-$-119.24M$135.2M-$-212.36M
Income tax expense$1.38M$6.08M-$-570K$10.9M-$-520K
Net income-$-81.13M-$-122.69M-$-118.67M$124.3M-$-211.84M
Weighted average shares outstanding$75.3M$75.9M$68.9M$65.2M$52.1M
Weighted average diluted shares outstanding$75.3M$75.9M$68.9M$65.3M$52.1M
Balance sheet
20252024202320222021
Cash and short-term investments$228.8M$225.8M$374.3M$492.2M$252.6M
Net receivables$4.64M$55.8M$19.5M$33.4M$15.6M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$233.4M$300.5M$412.9M$544.7M$288.2M
Property, plant and equipment, net$0.00$34.3M$37.5M$47.7M$49.8M
Goodwill and intangible assets$13.4B$16.6M$37.3M$38.4M$33.5M
Long-term investments$41.8M$98.4M$81.9M$890K$890K
Total non-current assets$113.1M$162.6M$168M$104M$100.9M
Total assets$346.5M$463.1M$580.9M$648.7M$389.1M
Accounts payable$4.4M$3.9M$6.21M$7.86M$5.17M
Short-term debt$3.47M$2.74M$4.26M$3.32M$1.31M
Deferred revenue$2.42M$25.6M$3.7M$2.35M$0.00
Total current liabilities$42.3M$88.3M$55.8M$95.6M$71.9M
Long-term debt$14.8M$15.8M$22.5M$24.8M$31M
Deferred revenue, non-current$14.6M$14.6M$32.9M$30.6M$32.9M
Total non-current liabilities$35.7M$36M$60.3M$60.1M$68.2M
Capital lease obligations$18.3M$18.5M$26.7M$28.1M$32.3M
Total liabilities$78M$124.3M$116.1M$155.8M$140M
Common stock$1.11B$1.02B$1.01B$906.8M$741.2M
Retained earnings-$-953.16M-$-830.34M-$-677.44M-$-558.76M-$-683.1M
Accumulated other comprehensive income (loss)-$-6.08M-$-6.95M-$-6.6M-$-6.66M-$-6.66M
Total equity$268.5M$338.8M$464.8M$493M$249.1M
Total investments$228.8M$258.1M$298.7M$92.2M$51.6M
Total debt$18.3M$18.5M$26.7M$28.1M$32.3M
Net debt-$-22.89M-$-47.6M-$-130.84M-$-372.8M-$-169.53M
Cash flow statement
20252024202320222021
Net income-$-81.13M-$-122.69M-$-118.67M$124.3M-$-211.84M
Depreciation and amortization$10.8M$11.2M$17.3M$12M$9.58M
Stock-based compensation$28M$17.8M$8.1M$4.01M$10.8M
Change in working capital$7.5M-$-30.95M-$-25.55M$4.01M$390K
Accounts receivable$51.2M-$-36.36M$13.9M-$-17.51M-$-270K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-23.65M$14.3M-$-44.77M$26.5M$16.5M
Net cash provided by operating activities-$-33.01M-$-110.04M-$-118.3M$144.1M-$-192.45M
Investments in property, plant and equipment-$-2.35M-$-1.99M-$-2.47M-$-13.12M-$-12.4M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$26.7M$38.8M-$-207.25M-$-53.85M$144.6M
Common stock issued$23.3M$0.00$76.1M$107.5M$0.00
Common stock repurchased-$-41.7M-$-30.05M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-18.56M-$-20.45M$81.9M$108.6M$8.01M
Net change in cash-$-24.95M-$-91.45M-$-243.35M$199M-$-40.17M
Cash at end of period$41.2M$66.1M$157.6M$400.9M$201.9M
Operating cash flow-$-33.01M-$-110.04M-$-118.3M$144.1M-$-192.45M
Capital expenditure-$-1.52M-$-3.07M-$-4.08M-$-13.12M-$-13.29M
Free cash flow-$-34.53M-$-113.11M-$-122.38M$131M-$-205.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Zymeworks Inc.

        Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

        CEO
        Kenneth H. Galbraith
        Employees
        264
        Beta
        1.13

        Explore

        Frequently asked questions

        What is the intrinsic value of Zymeworks Inc. (ZYME)?

        Zymeworks Inc. (ZYME) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ZYME undervalued?

        ZYME trades at a price of $26.14 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.